Preclinical and clinical researches have demonstrated that icotinib has a better efficacy in treating advanced NSCLC [7, 9], which specifically and competitively bind to tyrosine kinase, inhibit the enzymatic activity of EGFR, block the related signal conduction and thereby reduce cancer cell growth [10]. Here, EGFR is linked to non-small cell lung carcinoma.